Market LIVE
Published markets; coverage varies by country
Product profile · United States

DUTREBIS

 ·  Patent Litigation & Settlement History ↓

IngredientLAMIVUDINE; RALTEGRAVIR POTASSIUM
Application typeNDA
Application206510
Product001
Dosage formTABLET
RouteORAL
Strength150MG;EQ 300MG BASE
Approval date2015-02-06
Marketing statusDISCONTINUED
Status event—
ApplicantMERCK SHARP DOHME
Product source

Current GenericRadar decision

Year2015
SelectionDISQUALIFIED
ReviewFINAL
Anchor typeFDA_DISCONTINUATION
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date2029-09-11
First Final ANDA—
Status event—

FDA_DISCONTINUED; FDA DISC action month 2015-08

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
77547312029-03-11DS/DP/U U-1663———
———
77547312029-09-11— ————
—2029-09-11—
77547312029-09-11ORANGE_BOOK U-1663NNDP
English description not available.
—2029-09-11—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (2)
TypeDateRoleBasisSource
PATENT2029-09-11HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_STATUS—TERMINAL_STATUSFDA_DISCONTINUED; FDA DISC action month 2015-08Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.